anthonyyazdaniml/CT-ADE-SOC huggingface dataset:
Intervention: Minocycline
Trial phase: Not Applicable
ATC code: A01AB23 | D10AF07 | J01AA08 | J01AA20
SMILES: [H][C@@]12Cc3c(N(C)C)ccc(O)c3C(=O)C1=C(O)[C@]1(O)C(=O)C(C(N)=O)=C(O)[C@@H](N(C)C)[C@]1([H])C2
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 21
Group description: CRP > 3
Eligibility criteria:
Inclusion Criteria:

Patients with Bipolar Disorder and current depressive symptoms
Hamilton Depression Scale score > 18
Failed an adequate trial of at least one antidepressant or mood stabilizer of at least 4 weeks duration. Medication history will be recorded using the Antidepressant Treatment History Form
18 years or older
Fluent in English or Arabic
Have the capacity to understand the nature of the study and sign the written informed consent.

Exclusion Criteria:

A current diagnosis of Schizophrenia or other psychotic disorder, or Dementia Alzheimer Type or related cognitive disorders.
Principal diagnosis of Post-Traumatic Stress Disorder, Anorexia or Bulimia Nervosa, Obsessive-Compulsive Disorder. We define principal as the most pressing clinical problem.
Pregnant or nursing
Axis II diagnosis of antisocial, schizotypal or severe borderline personality disorder (defined as patients who are high risk for being unable to complete the study due to hospitalization, suicide attempts, significant self-mutilation, or other self-injurious or destructive behavior).
Patients who currently meet criteria for Alcohol or other Substance-Related Dependence Disorder (with the exception of nicotine dependence) who require detoxification.
Patients who are unable to read and write English or Arabic.
Patients having serious, unstable or terminal medical or neurologic illness that would compromise study participation (i.e., metastatic or advanced malignancy, chronic renal failure requiring dialysis, recent myocardial infarction or unstable angina, or "end stage" chronic obstructive pulmonary disease). People with common conditions such as hypertension, insulin dependent diabetes mellitus, asthma, compensated congestive heart failure, a malignancy in remission, treated hypothyroidism, or epilepsy will not be excluded from participation.
Autoimmune disease or chronic inflammatory diseases such as psoriasis or Crohn's disease
Chronic infection such as hepatitis B or C or HIV
Elevated antinuclear antibody or rheumatoid factor
Oral glucocorticoids in the past 6 months
Methotrexate or NSAID use in the past two weeks
Intervention: Victoza
Trial phase: Phase 4
ATC code: A10BJ02
SMILES: CCCCCCCCCCCCCCCC(=O)NC(CCC(=O)NCCCCC(NC(=O)C(C)NC(=O)C(C)NC(=O)C(CCC(N)=O)NC(=O)CNC(=O)C(CCC(=O)O)NC(=O)C(CC(C)C)NC(=O)C(Cc1ccc(O)cc1)NC(=O)C(CO)NC(=O)C(CO)NC(=O)C(NC(=O)C(CC(=O)O)NC(=O)C(CO)NC(=O)C(NC(=O)C(Cc1ccccc1)NC(=O)C(NC(=O)CNC(=O)C(CCC(=O)O)NC(=O)C(C)NC(=O)C(N)Cc1cnc[nH]1)C(C)O)C(C)O)C(C)C)C(=O)NC(CCC(=O)O)C(=O)NC(Cc1ccccc1)C(=O)NC(C(=O)NC(C)C(=O)NC(Cc1c[nH]c2ccccc12)C(=O)NC(CC(C)C)C(=O)NC(C(=O)NC(CCCNC(=N)N)C(=O)NCC(=O)NC(CCCNC(=N)N)C(=O)NCC(=O)O)C(C)C)C(C)CC)C(=O)O
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 16
Group description: Liraglutide subcutaneous injection once daily with following dose escalation:

liraglutide 0.6 mg once daily for one week; liraglutide 1.2 mg once daily for one week and thereafter liraglutide 1.8 mg once daily for 3.5 months.

Liraglutide
Eligibility criteria:
Inclusion Criteria:

Subjects with type 2 diabetes treated with a lifestyle or metformin (any dose)
waist circumference > 88 cm in women and > 92 cm in men
BMI 27-40 kg/m2
triglycerides between 1.0 - 4.0 mmol/L
LDL < 4.5 mmol/l

Exclusion Criteria:

Type 1 diabetes
Apo E2/2 phenotype
ALT/AST > 3x ULN
GFR < 60 ml/min, clinically significant TSH outside normal range
Lipid-lowering drugs other than statins within 6 months
Current treatment with pioglitazone, insulin, sulphonylureas, gliptins, glinides, SGLT-2 inhibitors or thiazide diuretics (at a dose of > 25 mg / day)
Blood pressure > 160 mmHg systolic and/or > 105 diastolic
History of pancreatitis or stomach / other major bleeding, thyroid neoplasia, persistent hypothyroidism or persistent hyperthyroidism
Any medical condition that puts the patient in the risk of dehydration
Concurrent medical condition that may interfere with the interpretation of efficacy and safety data during the study.
Females of childbearing potential who are not using adequate contraceptive methods
Subjects who have experienced side-effects previously from GLP-1 agonists
Non-compliance or withdrawal of consent
Any information or clinical event described in liraglutide SPC that is a contraindication for the use of liraglutide
Intervention: Daptomycin
Trial phase: Not Applicable
ATC code: J01XX09
SMILES: CCCCCCCCCC(=O)NC(Cc1c[nH]c2ccccc12)C(=O)NC(CC(N)=O)C(=O)NC(CC(=O)O)C(=O)NC1C(=O)NCC(=O)NC(CCCN)C(=O)NC(CC(=O)O)C(=O)NC(C)C(=O)NC(CC(=O)O)C(=O)NCC(=O)NC(CO)C(=O)NC(C(C)CC(=O)O)C(=O)NC(CC(=O)c2ccccc2N)C(=O)OC1C
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 3
Group description: Daily wound care with antibiotic ointments after cleansing plus evaluation using ICG/SPY fluorescence.

ICG/SPY: indocyanine green fluorescence imaging

Antibiotic Ointment: Antibiotic ointment
Eligibility criteria:
Inclusion Criteria:

patients with burn less than 15% TBSA

Exclusion Criteria:

none
Intervention: CID 443956
Trial phase: Phase 3
SMILES: COc1ccc(CC(C)NCC(O)c2ccc(O)c(NC=O)c2)cc1.COc1ccc(CC(C)NCC(O)c2ccc(O)c(NC=O)c2)cc1.O=C(O)C=CC(=O)O
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 644
Group description: Formoterol Fumarate Metered Dose Inhalation 9.6 μg
Eligibility criteria:
Inclusion Criteria:

Give their signed written informed consent to participate
Are at least 40 years of age and no older than 80 years
COPD patients who are symptomatic
Must be receiving one or more inhaled bronchodilators as maintenance therapy

Exclusion Criteria:

Current diagnosis of asthma,
COPD due to α1-Antitrypsin Deficiency
Known active tuberculosis, lung cancer, cystic fibrosis, significant bronchiectasis, Pulmonary resection or Lung Volume Reduction Surgery during the past 6 months
Long-term-oxygen therapy (≥ 12 hours a day).
Intervention: Budesonide
Trial phase: Phase 3
ATC code: A07EA06 | D07AC09 | R01AD05 | R03AK07 | R03AK12 | R03AL11 | R03BA02
SMILES: CCCC1OC2CC3C4CCC5=CC(=O)C=CC5(C)C4C(O)CC3(C)C2(C(=O)CO)O1
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 206
Group description: Budesonide Metered Dose Inhalation 320 μg
Eligibility criteria:
Inclusion Criteria:

Give their signed written informed consent to participate
Are at least 40 years of age and no older than 80 years
COPD patients who are symptomatic
Must be receiving one or more inhaled bronchodilators as maintenance therapy

Exclusion Criteria:

Current diagnosis of asthma,
COPD due to α1-Antitrypsin Deficiency
Known active tuberculosis, lung cancer, cystic fibrosis, significant bronchiectasis, Pulmonary resection or Lung Volume Reduction Surgery during the past 6 months
Long-term-oxygen therapy (≥ 12 hours a day).
Intervention: SODIUM CHLORIDE
Trial phase: Not Applicable
ATC code: A12CA01 | B05CB01 | B05XA03 | S01XA03
SMILES: [Cl-].[Na+]
Sex: All
Age groups: Child
Healthy volunteers: No
Participants at risk: 24
Group description: 3ml of 0.9% sterile saline will be administered via nebulizer and mechanical ventilator

Sterile Saline: Subjects will receive a dose of study medication every 4 hours for 24 total hours
Eligibility criteria:
Inclusion Criteria:

Infants greater than or equal to 36 weeks corrected gestational age to one year of age
Diagnosis of BPD in accordance with The Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) definition
May have a current order for short acting bronchodilator, not required
May have congenital anomalies unless one or more of the exclusion criteria are met, not required
Receiving conventional mechanical ventilation via an artificial airway (endotracheal tube or tracheostomy) via Draeger V500 Ventilator
Parental/guardian permission (informed consent)

Exclusion Criteria:

Airway leak greater than 10%
Unilateral lung disease
Current order for inhaled anticholinergic (i.e. ipratropium bromide)
Active pulmonary or systemic infection
Scheduled order for other medication that cause bronchodilation (i.e. atrovent, magnesium sulfate, ketamine, etc.)
Intervention: Lubiprostone
Trial phase: Phase 3
ATC code: A06AX03
SMILES: [H][C@@]12CC(=O)[C@H](CCCCCCC(=O)O)[C@@]1([H])CC[C@](O)(C(F)(F)CCCC)O2
Sex: All
Age groups: Child
Healthy volunteers: No
Participants at risk: 87
Group description: Participants received lubiprostone 12 mcg or 24 mcg BID (dose based on participant's weight) up to 24 weeks.
Eligibility criteria:
Inclusion Criteria:

Medically-confirmed diagnosis of Functional Constipation per Rome III Diagnostic Criteria for Childhood Functional Constipation
At least 6 years of age but less than 18 years of age at the time of randomisation
Only stable dose of selective serotonin re-uptake inhibitors (SSRIs), serotonin-specific reuptake inhibitor (SNRIs), or monoamine oxidase inhibitors (MAO) inhibitors are allowed if participant is taking antidepressants

Exclusion Criteria:

Any gastrointestinal (GI) condition, other than constipation, affecting GI motility or defecation
Untreated faecal impaction at the time of screening
Medical/surgical condition that might interfere with the absorption, distribution, metabolism, or excretion of the study medication
Intervention: Luliconazole
Trial phase: Phase 4
ATC code: D01AC18
SMILES: N#C/C(=C1/SC[C@@H](c2ccc(Cl)cc2Cl)S1)n1ccnc1
Sex: All
Age groups: Child
Healthy volunteers: No
Participants at risk: 15
Group description: Participants with tinea pedis received luliconazole cream 1% topically once daily in the morning for 15 days (Day 1 through 15). The dose was approximately 3.0 grams per application and covered all affected and adjacent areas.
Eligibility criteria:
Key Inclusion Criteria:

Participants (or legal guardian) with the ability and willingness to sign a written informed consent.
Participants of either gender at least 12 years to <18 years old (12 to 17 years, inclusive).
Participants with a mycological diagnosis of tinea pedis or tinea cruris confirmed by the detection of fungal hyphae on a microscopic potassium hydroxide (KOH) wet mount.
Participants with the ability and willingness to follow all study procedures, attend all scheduled visits, have all blood draws, and successfully complete the study.
Participants must be in good general health and free of any disease that in the Investigator's opinion might interfere with the study evaluations.
Participants must be able to communicate, be able to understand the study procedures, and be willing to comply with the study requirements.

Key Exclusion Criteria:

Participants with both tinea pedis and tinea cruris.
Participants with active atopic or contact dermatitis in the treatment area.
Female participants who are pregnant and/or nursing or planning a pregnancy during the course of the trial. Participants who test positive for pregnancy after start of test treatment will be discontinued from test treatment but will be followed for safety purposes.
Participants who are immunocompromised (due to disease, for example; human immunodeficiency virus [HIV] or medications).
Participants who have a recent history of or current drug or alcohol abuse.
Intervention: Luliconazole
Trial phase: Phase 4
ATC code: D01AC18
SMILES: N#C/C(=C1/SC[C@@H](c2ccc(Cl)cc2Cl)S1)n1ccnc1
Sex: All
Age groups: Child
Healthy volunteers: No
Participants at risk: 15
Group description: Participants with tinea cruris received luliconazole cream 1% topically once daily in the morning for 8 days (Day 1 through 8). The dose was approximately 3.0 grams per application and covered all affected and adjacent areas.
Eligibility criteria:
Key Inclusion Criteria:

Participants (or legal guardian) with the ability and willingness to sign a written informed consent.
Participants of either gender at least 12 years to <18 years old (12 to 17 years, inclusive).
Participants with a mycological diagnosis of tinea pedis or tinea cruris confirmed by the detection of fungal hyphae on a microscopic potassium hydroxide (KOH) wet mount.
Participants with the ability and willingness to follow all study procedures, attend all scheduled visits, have all blood draws, and successfully complete the study.
Participants must be in good general health and free of any disease that in the Investigator's opinion might interfere with the study evaluations.
Participants must be able to communicate, be able to understand the study procedures, and be willing to comply with the study requirements.

Key Exclusion Criteria:

Participants with both tinea pedis and tinea cruris.
Participants with active atopic or contact dermatitis in the treatment area.
Female participants who are pregnant and/or nursing or planning a pregnancy during the course of the trial. Participants who test positive for pregnancy after start of test treatment will be discontinued from test treatment but will be followed for safety purposes.
Participants who are immunocompromised (due to disease, for example; human immunodeficiency virus [HIV] or medications).
Participants who have a recent history of or current drug or alcohol abuse.
Intervention: Kenalog
Trial phase: Not Applicable
SMILES: CC1(C)OC2CC3C4CCC5=CC(=O)C=CC5(C)C4(F)C(O)CC3(C)C2(C(=O)CO)O1
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 90
Group description: Kenalog (40 mg of 40 mg/ml) will be the steroid utilized as the active comparator to be injected in the knee joint.

Kenalog: Active comparator, Kenalog steroid, will be injected into the articular space of the knee.
Eligibility criteria:
Inclusion Criteria:

Male or female, aged 18 to 80 years.
Willing and able to give voluntary informed consent to participate in this investigation.
Patient presents with knee osteoarthritis and Kellgren Lawrence grade 2-4 (OA diagnosed and confirmed by treating physician using standing x-ray).
Candidate for intra-articular knee injection.
BMI < 40

Exclusion Criteria:

Patients who have received intra-articular injection(s) in the last 3 months.
Patients who have undergone arthroscopic surgery on the study knee in the past year.
Patients who have undergone arthroplasty on the study knee.
Ligament instability
Diabetes (Type 1 or II)
Inflammatory arthropathies.
Fibromyalgia or chronic fatigue syndrome.
Female patient who is pregnant or nursing.
Chronic use of narcotics.
Any other reason (in the judgment of the investigator).
Intervention: Orlistat
Trial phase: Phase 2
ATC code: A08AB01
SMILES: CCCCCCCCCCC[C@@H](C[C@@H]1OC(=O)[C@H]1CCCCCC)OC(=O)[C@H](CC(C)C)NC=O
Sex: All
Age groups: Child | Adult
Healthy volunteers: No
Participants at risk: 2
Group description: Each of the two patients, were randomized to receive Orlistat for 3 months in two periods.

Patient 1 took Orlistat 60 mg with the first and second meal and 120 mg with the third meal, whereas Patient 2 took 60 mg of Orlistat 3 times daily with meals.
Eligibility criteria:
Inclusion Criteria:

Type I hyperlipoproteinemia
Fasting serum triglyceride levels of greater than 1000 mg/dL
Age > 8 years

Exclusion Criteria:

Secondary hypertriglyceridemias due to diabetes, renal disease, hypothyroidism, alcoholism and drug therapy such as estrogens and estrogen analogues, steroids, HIVprotease inhibitors, retinoic acid derivatives and interferons
Pregnant or lactating women
Significant liver disease (elevated transaminases > 2 times upper limit of normal) Alcohol abuse (> 7 drinks or 84 g per week for women and > 14 drinks or 168 g per week for men)
Severe anemia (hematocrit < 24%)
Drug use (cocaine, marijuana, LSD, etc.)
Major surgery in the past three months
Congestive heart failure
Serum creatinine greater than 2.5 mg/dL
Cancer within the past five years
Gastrointestinal surgery in the past
Current therapy with anti-coagulants, digoxin, and anti-arrhythmics
Current therapy with cyclosporine
Chronic malabsorption syndromes
Cholestasis
Acute illnesses such as acute pancreatitis in the last 8 weeks
Intervention: Oleanolic Acid
Trial phase: Phase 2
SMILES: CC1(C)CCC2(C(=O)O)CCC3(C)C(=CCC4C5(C)CCC(O)C(C)(C)C5CCC43C)C2C1
Sex: All
Age groups: Adult
Healthy volunteers: No
Participants at risk: 12
Group description: Banaba capsules, 500mg, two times per day before meals during 90 days

Banaba: Banaba capsules of 500 mg two times per day before meals with a total dosis of 1000 mg per day.
Eligibility criteria:
Inclusion Criteria:

Patients both sexes,
Age between 30 and 60 years,
Metabolic Syndrome according to the IDF criteria
Waist circumference
Man ≥90 cm
Woman ≥80 cm

And two of the following criteria:

High density lipoprotein
Man ≤40 mg/dL
Woman ≤50 mg/dL
Fasting glucose ≥100 mg/dL
Triglycerides ≥150 mg/dL
Blood pressure ≥130/85 mmHg
Informed consent signed

Exclusion Criteria:

Women with confirmed or suspected pregnancy
Women under lactation and/or puerperium
Hypersensibility to resveratrol
Physical impossibility for taking pills
Known uncontrolled renal, hepatic, heart or thyroid diseased
Previous treatment for the metabolic syndrome components
Body Mass Index ≥39.9 kg/m2
Fasting glucose ≥126 mg/dL
Triglycerides ≥500 mg/dL
Total cholesterol ≥240 mg/dL
Low density lipoprotein (c-LDL) ≥190 mg/dL
Blood Pressure ≥140/90 mmHg
Intervention: Luliconazole
Trial phase: Phase 4
ATC code: D01AC18
SMILES: N#C/C(=C1/SC[C@@H](c2ccc(Cl)cc2Cl)S1)n1ccnc1
Sex: All
Age groups: Child
Healthy volunteers: No
Participants at risk: 60
Group description: Luliconazole cream 1% was applied once daily in the morning for 7 days to the area affected with tinea corporis and approximately 1 inch of the immediate surrounding area.
Eligibility criteria:
Key Inclusion Criteria:

Participants (or legal guardian/caregiver) with the ability and willingness to sign a written informed consent and/or assent (age appropriate).
Participants of either gender must be at least 2 years to less than (<) 18 years of age (2 to 17 years, inclusive).
Participants with a clinical diagnosis of tinea corporis characterized by clinical evidence of a tinea infection (at least moderate erythema, mild scaling, and moderate pruritus).
Participants must be in good general health and free of any disease that in the Investigator's opinion might interfere with the study evaluations.
Participants/caregiver must be able to communicate, be able to understand the study procedures, and be willing to comply with the study requirements.

Key Exclusion Criteria:

Participants with active atopic or contact dermatitis in the area to be treated.
Participants with severe dermatophytoses, mucocutaneous candidiasis, or bacterial skin infection.
Female participants who are pregnant and/or nursing or planning a pregnancy during the course of the trial. Participants who test positive for pregnancy after start study drug will be discontinued from study drug but will be followed for safety purposes.
Participants who are immunocompromised (due to disease, for example; human immunodeficiency virus [HIV] or medications).
Participants who have a recent history of or current drug or alcohol abuse.
Intervention: Betamethasone
Trial phase: Phase 3
ATC code: A01AC02 | A07EA04 | C05AA05 | C05AA09 | D07AB19 | D07AC01 | D07BC01 | D07CB04 | D07CC01 | D07XB05 | D07XC01 | D10AA03 | H02AB01 | H02AB02 | R01AD03 | R01AD06 | R01AD53 | R03BA04 | S01BA01 | S01BA06 | S01BB04 | S01CA01 | S01CA05 | S01CB01 | S01CB04 | S02BA06 | S02BA07 | S02CA06 | S03BA01 | S03BA03 | S03CA01 | S03CA06
SMILES: CC1CC2C3CCC4=CC(=O)C=CC4(C)C3(F)C(O)CC2(C)C1(O)C(=O)CO
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 142
Group description: 12 mg dexamethasone

OTO-104: Intratympanic injection of 12 mg OTO-104
Eligibility criteria:
Inclusion Criteria includes, but is not limited to:

Subject has completed the Phase 2 OTO-104 1-Year Safety Study (104-201403) or Phase 3 (104-201508) clinical study.
Subject has a diagnosis of definite unilateral Meniere's disease by 1995 AAO-HNS criteria

Exclusion Criteria includes, but is not limited to:

Subject is pregnant or lactating.
Subject has a history of immunodeficiency disease.
Subject has experienced an adverse reaction to intratympanic injection of steroids.
Intervention: Acthargel
Trial phase: Phase 4
SMILES: CSCCC(NC(=O)C(CO)NC(=O)C(Cc1ccc(O)cc1)NC(=O)C(N)CO)C(=O)NC(CCC(=O)O)C(=O)NC(Cc1cnc[nH]1)C(=O)NC(Cc1ccccc1)C(=O)NC(CCCNC(=N)N)C(=O)NC(Cc1c[nH]c2ccccc12)C(=O)NCC(=O)NC(CCCCN)C(=O)N1CCCC1C(=O)NC(C(=O)NCC(=O)NC(CCCCN)C(=O)NC(CCCCN)C(=O)NC(CCCNC(=N)N)C(=O)NC(CCCNC(=N)N)C(=O)N1CCCC1C(=O)NC(C(=O)NC(CCCCN)C(=O)NC(C(=O)NC(Cc1ccc(O)cc1)C(=O)N1CCCC1C(=O)NC(CC(N)=O)C(=O)NCC(=O)NC(C)C(=O)NC(CCC(=O)O)C(=O)NC(CC(=O)O)C(=O)NC(CCC(=O)O)C(=O)NC(CO)C(=O)NC(C)C(=O)NC(CCC(=O)O)C(=O)NC(C)C(=O)NC(Cc1ccccc1)C(=O)N1CCCC1C(=O)NC(CC(C)C)C(=O)NC(CCC(=O)O)C(=O)NC(Cc1ccccc1)C(=O)O)C(C)C)C(C)C)C(C)C
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 2
Group description: Acthar 80 IU SC twice week
Eligibility criteria:
Inclusion Criteria:

Active anterior uveitis requiring oral and/or topical corticosteroid therapy

Exclusion Criteria:

Uncontrolled diabetes
Uncontrolled glaucoma
HIV infection or other infection for which corticosteroid therapy contraindicated
Contraindication to ACTHAR
Scleroderma
Osteoporosis
Ocular herpes simplex
Systemic fungal infection
Recent surgery
Uncontrolled hypertension
Intervention: Brimonidine/brinzolamide
Trial phase: Phase 4
SMILES: Brc1c(NC2=NCCN2)ccc2nccnc12.CCNC1CN(CCCOC)S(=O)(=O)c2sc(S(N)(=O)=O)cc21
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 64
Group description: All subjects exposed to SIMBRINZA
Eligibility criteria:
Inclusion Criteria:

Diagnosis of either open-angle glaucoma or ocular hypertension;
Able to attend all study related visits and be housed overnight at clinical site for the study assessments;
Willing and able to sign an informed consent form;
Other protocol-specified inclusion criteria may apply.

Exclusion Criteria:

Women of childbearing potential who are pregnant, intend to become pregnant during the study, breast-feeding, or not using adequate birth control;
Diagnosed with any form of glaucoma other than open angle glaucoma or ocular hypertension;
Ocular surgeries or procedures excluded by the protocol;
Diseases, illnesses, infections, or ocular abnormalities excluded by the protocol;
Best-corrected visual acuity score less than 55 ETDRS letters (equivalent to approximately 20/80 Snellen) in either eye;
Other protocol-specific exclusion criteria may apply.